Financial Summary
Aptevo Therapeutics Inc. (APVO)
| Symbol | APVO |
|---|---|
| Price | 8.45$ |
| Beta | 2.51 |
| Volume Avrg. | 0.66M |
| Market Cap | 0.03B |
| Shares (2019) | 40,838.49K |
| Last Div | 0 |
| Dividend Yield | - |
| DCF Unlevered | - | |
|---|---|---|
| DCF Levered | - | |
| ROE | -341.56% | Strong Sell |
| ROA | -75.73% | Strong Sell |
| Operating Margin | -131.37% | Strong Sell |
| Debt / Equity | 351.00% | Strong Buy |
| P/E | -8.91 | Strong Sell |
| P/B | 30.42 | Strong Buy |
Income Statement
Quarter data| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Earnings Per Share Diluted | -5.55 | 0.33 | -2.39 | -0.99 |
| Net Profit Margin | -3.09 | 0.48 | -2.33 | -1.25 |
| Weighted Average Shares Outstanding | 21.14 | 22.03 | 40.84 | 40.84 |
| Revenue | 36.43 | 14.66 | 23.07 | 32.42 |
| Weighted Average Shares Outstanding (Diluted) | 20.24 | 21.34 | 22.50 | 40.84 |
| Gross Profit | 12.25 | 9.65 | 11.85 | 12.50 |
| Dividend per Share | - | - | - | - |
| Operating Income | -126.94 | -53.95 | -51.66 | -42.60 |
| Gross Margin | 0.34 | 0.66 | 0.51 | 0.39 |
| Income Tax Expense | -15.34 | -23.30 | - | - |
| EBIT Margin | -3.39 | -3.47 | -2.14 | -1.24 |
| Net Income | -112.42 | 6.97 | -53.69 | -40.45 |
| Cost of Revenue | 24.18 | 5.01 | 11.21 | 19.93 |
| Earnings Before Tax Margin | -3.51 | -3.81 | -2.33 | -1.38 |
| EBIT | -126.94 | -53.95 | -51.66 | -42.60 |
| EBITDA | -123.58 | -50.82 | -49.27 | -40.36 |
| Profit Margin | -3.09 | 0.48 | -2.33 | -1.25 |
| Operating Expenses | 68.18 | 63.60 | 63.52 | 55.09 |
| Earnings Per Share Basic | -5.55 | 0.33 | -2.39 | -0.99 |
| Earnings before Tax | -127.75 | -55.89 | -53.69 | -44.70 |
| Interest Expense | - | - | - | - |
Balance Sheet Statement
Quarter data| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Short-term debt | - | 3.33 | 0.80 | 19.86 |
| Other Assets | - | 10.00 | 8.35 | 15.05 |
| Total current liabilities | 19.54 | 18.51 | 17.61 | 38.24 |
| Cash and cash equivalents | 9.68 | 7.09 | 30.64 | 12.45 |
| Long-term debt | 18.38 | 15.73 | 19.28 | 3.33 |
| Cash and short-term investments | 54.52 | 80.78 | 30.74 | 24.94 |
| Total debt | 18.38 | 19.06 | 20.07 | 23.19 |
| Inventories | 6.64 | 1.03 | 1.78 | 6.14 |
| Deferred revenue | 0.81 | - | - | - |
| Goodwill and Intangible Assets | 14.53 | 6.08 | 5.25 | 4.42 |
| Total non-current liabilities | 22.32 | 16.69 | 19.48 | 3.33 |
| Total non-current assets | 20.44 | 21.92 | 18.80 | 23.41 |
| Total liabilities | 41.29 | 34.97 | 37.09 | 41.57 |
| Total assets | 91.86 | 117.01 | 67.49 | 53.41 |
| Other comprehensive income | 131.27 | 155.84 | 157.79 | 179.65 |
| Short-term investments | 44.85 | 73.69 | 0.10 | 12.49 |
| Property, Plant & Equipment Net | 5.91 | 5.84 | 5.20 | 3.95 |
| Net Debt | 8.71 | 11.97 | -10.56 | 10.74 |
| Investments | 44.85 | 73.69 | 0.10 | 12.49 |
| Total shareholders equity | 50.57 | 82.03 | 30.41 | 11.84 |
| Retained earnings (deficit) | -80.69 | -73.72 | -127.41 | -167.86 |
| Long-term investments | - | - | - | - |
| Receivables | 4.28 | 2.14 | 5.22 | 7.02 |
| Payables | 11.49 | 7.35 | 11.67 | 13.04 |
| Total current assets | 71.41 | 95.08 | 48.69 | 30.00 |
Cash Flow Statement
Quarter data| Year | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Investing Cash Flow | -47.39 | 29.46 | 72.80 | 4.10 |
| Free Cash Flow | -39.37 | -42.98 | -52.40 | -42.54 |
| Depreciation & Amortization | 3.36 | 3.13 | 2.39 | 2.23 |
| Net cash flow / Change in cash | 5.04 | -2.58 | 20.59 | -18.14 |
| Effect of forex changes on cash | - | - | - | - |
| Financing Cash Flow | 89.30 | 9.53 | -0.79 | 20.15 |
| Dividend payments | - | - | - | - |
| Stock-based compensation | 3.81 | 4.88 | 2.14 | 1.60 |
| Investment purchases | -44.88 | -99.63 | -16.54 | - |
| Acquisitions and disposals | - | - | - | - |
| Capital Expenditure | 2.51 | 1.40 | 0.98 | 0.15 |
| Operating Cash Flow | -36.86 | -41.57 | -51.42 | -42.38 |
Retained Earning Schedule
| Year | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Retained Earnings (Previous Year) | - | -81 | -74 | -127 |
| Net Income | -112 | 7 | -54 | -40 |
| Stock Dividends | 32 | - | - | - |
| Dividend Paid | - | - | - | - |
| Retained Earnings | -81 | -74 | -127 | -168 |
PPE Schedule
| Year | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Gross PPE | - | 6 | 6 | 5 |
| Annual Depreciation | 3 | -1 | -2 | -1 |
| Capital Expenditure | 3 | 1 | 1 | 0 |
| Net PPE | 6 | 6 | 5 | 4 |
Intangible and Goodwill Schedule
| Year | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Intangible and Goodwill (Previous Year) | - | 15 | 6 | 5 |
| New Purchases | -45 | -100 | -17 | - |
| Intangible and Goodwill | 15 | 6 | 5 | 4 |
About
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed product includes IXINITY, a coagulation factor IX therapeutic indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations. Its lead clinical candidate is APVO436, a bispecific immunotherapeutic protein that is in Phase 1/1b clinical trial for acute myeloid leukemia and high-grade myelodysplastic syndrome. The company's preclinical candidates include ALG.APV-527, a bispecific antibody to target 4-1BB x 5T4; APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; and other pre-clinical development stage therapeutics focused on immuno-oncology. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo